Blueprint Medicines Corp. (NASDAQ:BPMC) Director Daniel Lynch sold 21,800 shares of the business’s stock in a transaction dated Thursday, October 13th. The stock was sold at an average price of $30.02, for a total value of $654,436.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) opened at 28.90 on Tuesday. Blueprint Medicines Corp. has a 52 week low of $13.04 and a 52 week high of $30.90. The firm has a 50-day moving average price of $28.15 and a 200 day moving average price of $22.05. The stock’s market cap is $786.86 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its earnings results on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.03. The business had revenue of $7.07 million for the quarter, compared to analysts’ expectations of $4.41 million. Blueprint Medicines Corp. had a negative return on equity of 46.01% and a negative net margin of 284.85%. The business’s revenue for the quarter was up 163.0% on a year-over-year basis. During the same period last year, the firm posted ($0.81) earnings per share. On average, analysts forecast that Blueprint Medicines Corp. will post ($3.05) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Blueprint Medicines Corp. (NASDAQ:BPMC)

Several research analysts have recently commented on BPMC shares. Zacks Investment Research raised Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Thursday, August 11th. Canaccord Genuity started coverage on Blueprint Medicines Corp. in a report on Friday, August 5th. They set a “buy” rating and a $26.00 price objective for the company. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. TheStreet raised Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. Finally, Wedbush reissued an “outperform” rating and set a $41.00 price objective on shares of Blueprint Medicines Corp. in a report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Blueprint Medicines Corp. currently has an average rating of “Buy” and an average target price of $30.00.

Hedge funds and other institutional investors have recently made changes to their positions in the company. BVF Inc. IL boosted its position in shares of Blueprint Medicines Corp. by 15.9% in the first quarter. BVF Inc. IL now owns 2,640,251 shares of the company’s stock valued at $47,657,000 after buying an additional 361,792 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Blueprint Medicines Corp. by 46.8% in the second quarter. BlackRock Fund Advisors now owns 871,793 shares of the company’s stock valued at $17,654,000 after buying an additional 277,781 shares during the last quarter. State Street Corp boosted its position in shares of Blueprint Medicines Corp. by 142.4% in the second quarter. State Street Corp now owns 325,396 shares of the company’s stock valued at $6,587,000 after buying an additional 191,138 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Blueprint Medicines Corp. by 41.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 328,630 shares of the company’s stock valued at $6,655,000 after buying an additional 96,761 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of Blueprint Medicines Corp. by 65.9% in the second quarter. Lord Abbett & CO. LLC now owns 210,581 shares of the company’s stock valued at $4,264,000 after buying an additional 83,677 shares during the last quarter. 73.65% of the stock is currently owned by institutional investors and hedge funds.

About Blueprint Medicines Corp.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Receive News & Stock Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related stocks with our FREE daily email newsletter.